Integrated analysis reveals CXCL12+ pericytes promote lymphatic metastasis in pancreatic cancer, indicating a potential therapeutic target.
4126 Background: Pancreatic ductal adenocarcinoma (PDAC) exhibits poor prognosis largely due to early lymph node metastasis, yet the cellular and molecular mechanisms governing lymphatic dissemination remain incompletely understood. Methods: We integrated multi-omics approaches including single-cell RNA sequencing (scRNA-seq) of 19 PDAC samples, spatial transcriptomics of 6 specimens, bulk RNA sequencing of 174 cases, and multiplex immunofluorescence of 166 clinical samples stratified by lymph node metastasis status. Cell-cell communication analysis, trajectory inference, and functional validation were performed to elucidate pro-metastatic mechanisms. Results: Single-cell profiling of 145,283 cells revealed substantial cellular heterogeneity, with fibroblasts and pericytes serving as dominant signaling hubs within the tumor microenvironment. Lymph node metastasis-positive (pLNM) tumors exhibited enhanced stromal-epithelial crosstalk mediated by PTN and ANGPT pathways. We identified invasive epithelial subpopulations (Epi_MUC5AC_CD24 and Epi_NEAT1_MALAT1) significantly enriched in pLNM samples, characterized by activation of EMT and invasion-related programs. Critically, high-resolution subclustering uncovered a CXCL12-expressing pericyte subset (PCs_CXCL12) preferentially expanded in metastatic tumors. Multiplex immunofluorescence validation in 166 specimens demonstrated that CXCL12+ pericyte infiltration correlated with perineural invasion, lymph node metastasis, advanced TNM stage, and inferior survival outcomes. Multivariate analysis established CXCL12+ pericyte score as an independent prognostic factor for both disease-free and overall survival. Mechanistically, we identified MYC as the master transcriptional regulator driving CXCL12 secretion in pericytes. Functional studies revealed that MYC-driven pericyte-derived CXCL12 promoted PDAC cell proliferation, invasion, and EMT. Spatial transcriptomics demonstrated co-localization of MYC, CXCL12, and its receptor CXCR4 in perineural pericyte niches. Orthotopic xenograft models confirmed that pericyte-specific Myc depletion significantly reduced tumor growth, CXCL12+ pericyte density, and tumor-associated lymphangiogenesis. Conclusions: This study establishes the pericyte MYC-CXCL12 axis as a critical driver of PDAC lymphatic metastasis through promotion of tumor cell invasion, EMT, and lymphangiogenesis. CXCL12+ pericytes represent a novel prognostic biomarker and potential therapeutic target for preventing lymph node metastasis in PDAC patients.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: